Nama's AI scorecard currently rates AtriCure Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ATRC's P/E ratio?

AtriCure trades at a trailing price-to-earnings ratio of 146.3.

When does ATRC report earnings?

AtriCure's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $0.08.

What is the ATRC price target?

The median analyst price target from 9 analysts is $62.00, with a range of $50.00 – $68.00.

Is ATRC Shariah compliant?

Nama's AAOIFI-style screen reads AtriCure as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

AtriCure (ATRC)

Healthcare · Medical Instruments Supplies · NASDAQ

AtriCure (ATRC) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $2.98B, a trailing price-to-earnings ratio of 146.3 and a free-cash-flow yield of 1.5%. Over the most recent reported fiscal year, revenue grew 14.9%. Nama's AI scorecard rates it Buy, 5.9 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 5.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Leading · +69.2% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-33.1%

How far the last close sits under the highest price of the past five years.

Market cap	$2.98B
Trailing P/E	146.3
Price / book	5.8
Price / sales	5.2
FCF yield	1.5%
Dividend yield	—
Gross margin	75.6%
Operating margin	1.1%
Net margin	0.8%
Revenue growth (YoY)	+14.9%
Revenue growth (3-yr annual)	+17.4%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

ATRC earnings

Next report: Feb 16, 2027 (Q4 2026, EPS estimate $0.08). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$0.17	$0.01	+1600.0%	$154.45M
Q2 2026	Jul 23, 2026	$0.18	$0.02	+800.0%	$153.60M
Q4 2025	Feb 17, 2026	$0.06	-$0.04	+250.0%	$140.50M
Q3 2025	Oct 29, 2025	-$0.01	-$0.12	+91.7%	$134.27M

ATRC analyst price target

Median target $62.00 from 9 analysts, ranging $50.00 – $68.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live ATRC data on Nama Insights →

Recent Congressional trades

AtriCure trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Gilbert Cisneros	House	Sell	$1,001 - $15,000	Oct 12, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Sep 10, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Apr 7, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jun 6, 2025
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 15, 2024
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jul 9, 2024

ATRC FAQ

Is ATRC a buy?: Nama's AI scorecard currently rates AtriCure Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ATRC's P/E ratio?: AtriCure trades at a trailing price-to-earnings ratio of 146.3.
When does ATRC report earnings?: AtriCure's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $0.08.
What is the ATRC price target?: The median analyst price target from 9 analysts is $62.00, with a range of $50.00 – $68.00.
Is ATRC Shariah compliant?: Nama's AAOIFI-style screen reads AtriCure as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.